EGFR (T790M/L792H/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.T790M;p.L792H;p.L858R
Components
p.T790Mp.L792Hp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Lazertinib | 97.7% | 2.3% | 97.47 |
| 2 | Canertinib | 93.4% | 6.6% | 96.49 |
| 3 | Osimertinib | 90.6% | 9.4% | 97.24 |
| 4 | Mobocertinib | 89.2% | 10.8% | 97.22 |
| 5 | Dacomitinib | 75.9% | 24.1% | 97.99 |
| 6 | Brigatinib | 55.6% | 44.4% | 82.96 |
| 7 | Fostamatinib | 45.8% | 54.2% | 96.74 |
| 8 | Capmatinib | 45.0% | 55.0% | 99.75 |
| 9 | Pacritinib | 37.0% | 63.0% | 88.64 |
| 10 | Neratinib | 27.3% | 72.7% | 93.18 |
| 11 | Ibrutinib | 24.6% | 75.4% | 94.74 |
| 12 | Temsirolimus | 13.0% | 87.0% | 100.00 |
| 13 | Vemurafenib | 12.3% | 87.7% | 96.49 |
| 14 | Alpelisib | 10.8% | 89.3% | 97.22 |
| 15 | Entrectinib | 10.4% | 89.6% | 93.69 |
| 16 | Mitapivat | 9.4% | 90.6% | 100.00 |
| 17 | Ruxolitinib | 9.0% | 91.0% | 98.25 |
| 18 | Deucravacitinib | 8.8% | 91.2% | 98.99 |
| 19 | Palbociclib | 7.8% | 92.2% | 98.75 |
| 20 | Regorafenib | 7.0% | 93.0% | 95.99 |
| 21 | Pirtobrutinib | 6.8% | 93.2% | 99.49 |
| 22 | Tenalisib | 6.3% | 93.7% | 97.98 |
| 23 | Pemigatinib | 6.3% | 93.7% | 98.23 |
| 24 | Gilteritinib | 6.2% | 93.8% | 88.97 |
| 25 | Lenvatinib | 6.1% | 93.9% | 97.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Lazertinib | 97.7% | 100.0% | -2.3% |
| Canertinib | 93.4% | 98.4% | -5.0% |
| Osimertinib | 90.6% | 99.1% | -8.5% |
| Mobocertinib | 89.2% | 100.0% | -10.8% |
| Dacomitinib | 75.9% | 99.8% | -23.9% |
| Brigatinib | 55.6% | 98.5% | -42.8% |
| Fostamatinib | 45.8% | 97.8% | -52.0% |
| Capmatinib | 45.0% | — | — |
| Pacritinib | 37.0% | — | — |
| Neratinib | 27.3% | 100.0% | -72.7% |
| Ibrutinib | 24.6% | 99.3% | -74.8% |
| Temsirolimus | 13.0% | — | — |
| Vemurafenib | 12.3% | — | — |
| Alpelisib | 10.8% | — | — |
| Entrectinib | 10.4% | — | — |
| Mitapivat | 9.4% | — | — |
| Ruxolitinib | 9.0% | — | — |
| Deucravacitinib | 8.8% | — | — |
| Palbociclib | 7.8% | — | — |
| Regorafenib | 7.0% | — | — |
| Pirtobrutinib | 6.8% | — | — |
| Tenalisib | 6.3% | — | — |
| Pemigatinib | 6.3% | — | — |
| Gilteritinib | 6.2% | 91.0% | -84.8% |
| Lenvatinib | 6.1% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 40.0ms